253 related articles for article (PubMed ID: 22419713)
1. Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study.
Ramírez C; Cheng S; Vargas G; Asa SL; Ezzat S; González B; Cabrera L; Guinto G; Mercado M
J Clin Endocrinol Metab; 2012 May; 97(5):1745-51. PubMed ID: 22419713
[TBL] [Abstract][Full Text] [Related]
2. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
Vieria Neto L; Wildemberg LE; Colli LM; Kasuki L; Marques NV; Moraes AB; Gasparetto EL; Takiya CM; Castro M; Gadelha MR
PLoS One; 2013; 8(10):e77406. PubMed ID: 24098585
[TBL] [Abstract][Full Text] [Related]
3. Estrogen Receptor α, a Sex-Dependent Predictor of Aggressiveness in Nonfunctioning Pituitary Adenomas: SSTR and Sex Hormone Receptor Distribution in NFPA.
Øystese KA; Casar-Borota O; Normann KR; Zucknick M; Berg JP; Bollerslev J
J Clin Endocrinol Metab; 2017 Sep; 102(9):3581-3590. PubMed ID: 28911153
[TBL] [Abstract][Full Text] [Related]
4. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
5. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness.
Qian ZR; Sano T; Asa SL; Yamada S; Horiguchi H; Tashiro T; Li CC; Hirokawa M; Kovacs K; Ezzat S
J Clin Endocrinol Metab; 2004 Apr; 89(4):1904-11. PubMed ID: 15070963
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast Growth Factor Receptor-4 Expression in Pituitary Adenomas is Associated with Aggressive Tumor Features.
Durcan E; Keskin FE; Ozkaya HM; Sirolu S; Sahin S; Korkmaz OP; Gazioglu N; Tanriover N; Comunoglu N; Oz B; Kizilkilic O; Kadioglu P
Exp Clin Endocrinol Diabetes; 2022 Feb; 130(2):125-133. PubMed ID: 34255320
[TBL] [Abstract][Full Text] [Related]
7. PTTG and Ki-67 expression in pituitary adenomas.
Wierzbicka-Tutka I; Sokołowski G; Bałdys-Waligórska A; Adamek D; Radwańska E; Gołkowski F
Przegl Lek; 2016; 73(2):53-8. PubMed ID: 27197423
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
Taboada GF; Luque RM; Bastos W; Guimarães RF; Marcondes JB; Chimelli LM; Fontes R; Mata PJ; Filho PN; Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
[TBL] [Abstract][Full Text] [Related]
9. Expression of somatostatin receptors, angiogenesis and proliferation markers in pituitary adenomas: an immunohistochemical study with diagnostic and therapeutic implications.
Magagna-Poveda A; Leske H; Schmid C; Bernays R; Rushing EJ
Swiss Med Wkly; 2013; 143():w13895. PubMed ID: 24222652
[TBL] [Abstract][Full Text] [Related]
10. Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma).
Yu B; Zhang Z; Song H; Chi Y; Shi C; Xu M
Med Sci Monit; 2017 Apr; 23():1947-1955. PubMed ID: 28434012
[TBL] [Abstract][Full Text] [Related]
11. Dopamine 2 and somatostatin 1-5 receptors coexpression in clinically non-functioning pituitary adenomas.
Gabalec F; Drastikova M; Cesak T; Netuka D; Masopust V; Machac J; Marek J; Cap J; Beranek M
Physiol Res; 2015; 64(3):369-77. PubMed ID: 25536318
[TBL] [Abstract][Full Text] [Related]
12. Prothymosin-alpha and Ki-67 expression in pituitary adenomas.
Wierzbicka-Tutka I; Sokołowski G; Bałdys-Waligórska A; Adamek D; Radwańska E; Gołkowski F
Postepy Hig Med Dosw (Online); 2016 Nov; 70(0):1117-1123. PubMed ID: 27892895
[TBL] [Abstract][Full Text] [Related]
13. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas.
Yao X; Gao H; Li C; Wu L; Bai J; Wang J; Li Y; Zhang Y
J Neurooncol; 2017 Apr; 132(2):199-206. PubMed ID: 28255749
[TBL] [Abstract][Full Text] [Related]
15. A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience.
Rishi A; Sharma MC; Sarkar C; Jain D; Singh M; Mahapatra AK; Mehta VS; Das TK
Neurol India; 2010; 58(3):418-23. PubMed ID: 20644271
[TBL] [Abstract][Full Text] [Related]
16. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
Padova H; Rubinfeld H; Hadani M; Cohen ZR; Nass D; Taylor JE; Culler MD; Shimon I
Mol Cell Endocrinol; 2008 May; 286(1-2):214-8. PubMed ID: 18276067
[TBL] [Abstract][Full Text] [Related]
17. SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary.
Lee M; Lupp A; Mendoza N; Martin N; Beschorner R; Honegger J; Schlegel J; Shively T; Pulz E; Schulz S; Roncaroli F; Pellegata NS
Endocr Relat Cancer; 2015 Feb; 22(1):111-9. PubMed ID: 25515731
[TBL] [Abstract][Full Text] [Related]
18. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor subtype gene expression in pituitary adenomas.
Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
[TBL] [Abstract][Full Text] [Related]
20. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.
Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR
Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
